FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2382179855> ?p ?o ?g. }

• W2382179855 endingPage "645" @default.
• W2382179855 startingPage "640" @default.
• W2382179855 abstract "AXP107-11 is a novel, multi-component crystalline form of the naturally occurring compound genistein. AXP107-11 has improved physiochemical properties and oral bioavailability compared to the natural form of genistein, and it is possible that combining AXP107-11 with chemotherapy may increase the effect and reduce chemoresistance. The purpose of this dose escalation phase Ib study was to assess the safety, maximum tolerated dose (MTD) and pharmacokinetics (PK) of AXP107-11 in combination with gemcitabine in treatment-naïve patients with inoperable pancreatic carcinoma.AXP107-11 was given orally in escalating doses (400 mg-1600 mg daily) in combination with standard gemcitabine treatment (1000 mg/m(2)/week) for the first seven of eight weeks and thereafter for a maximum of four × four-week treatment cycles. PK, safety, MTD and efficacy of AXP107-11 in combination with gemcitabine were evaluated.Sixteen patients were enrolled and received AXP107-11. The maximum concentration in serum of unconjugated (free) genistein was 1 μM. Neither dose-limiting toxicities (DLTs) nor signs of hematological or non-hematological toxicities related to AXP107-11 were observed over a period ranging from 0.7 to 13.2 months. The median overall survival time was 4.9 months (range 1.5-19.5 months). Seven patients (44%) survived longer than six months and 19% were alive at the one-year follow-up.Treatment of pancreatic cancer patients with AXP107-11 in combination with gemcitabine resulted in a favorable PK-profile with high serum levels without signs of either hematological or non-hematological toxicity. Accordingly, we suggest further studies with AXP107-11 in pancreatic cancer patients." @default.
• W2382179855 created "2016-06-24" @default.
• W2382179855 creator A5018053923 @default.
• W2382179855 creator A5037753016 @default.
• W2382179855 creator A5043422412 @default.
• W2382179855 creator A5067118869 @default.
• W2382179855 creator A5071823141 @default.
• W2382179855 creator A5072698735 @default.
• W2382179855 creator A5086605052 @default.
• W2382179855 date "2016-07-01" @default.
• W2382179855 modified "2023-10-17" @default.
• W2382179855 title "A phase I dose escalation trial of AXP107-11, a novel multi-component crystalline form of genistein, in combination with gemcitabine in chemotherapy-naive patients with unresectable pancreatic cancer" @default.
• W2382179855 cites W1917619044 @default.
• W2382179855 cites W1931508686 @default.
• W2382179855 cites W1967945780 @default.
• W2382179855 cites W1968812902 @default.
• W2382179855 cites W1979111318 @default.
• W2382179855 cites W1979342940 @default.
• W2382179855 cites W1994508517 @default.
• W2382179855 cites W2013886816 @default.
• W2382179855 cites W2014742104 @default.
• W2382179855 cites W2017911917 @default.
• W2382179855 cites W2019607817 @default.
• W2382179855 cites W2037608659 @default.
• W2382179855 cites W2039225116 @default.
• W2382179855 cites W2057280155 @default.
• W2382179855 cites W2059095722 @default.
• W2382179855 cites W2098646733 @default.
• W2382179855 cites W2103052708 @default.
• W2382179855 cites W2116502702 @default.
• W2382179855 cites W2132318505 @default.
• W2382179855 cites W2132847855 @default.
• W2382179855 cites W2138155367 @default.
• W2382179855 cites W2141825413 @default.
• W2382179855 cites W2151253787 @default.
• W2382179855 cites W2161498908 @default.
• W2382179855 cites W2169961966 @default.
• W2382179855 cites W4211208840 @default.
• W2382179855 cites W4250615339 @default.
• W2382179855 doi "https://doi.org/10.1016/j.pan.2016.05.002" @default.
• W2382179855 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27234064" @default.
• W2382179855 hasPublicationYear "2016" @default.
• W2382179855 type Work @default.
• W2382179855 sameAs 2382179855 @default.
• W2382179855 citedByCount "34" @default.
• W2382179855 countsByYear W23821798552017 @default.
• W2382179855 countsByYear W23821798552018 @default.
• W2382179855 countsByYear W23821798552019 @default.
• W2382179855 countsByYear W23821798552020 @default.
• W2382179855 countsByYear W23821798552021 @default.
• W2382179855 countsByYear W23821798552022 @default.
• W2382179855 countsByYear W23821798552023 @default.
• W2382179855 crossrefType "journal-article" @default.
• W2382179855 hasAuthorship W2382179855A5018053923 @default.
• W2382179855 hasAuthorship W2382179855A5037753016 @default.
• W2382179855 hasAuthorship W2382179855A5043422412 @default.
• W2382179855 hasAuthorship W2382179855A5067118869 @default.
• W2382179855 hasAuthorship W2382179855A5071823141 @default.
• W2382179855 hasAuthorship W2382179855A5072698735 @default.
• W2382179855 hasAuthorship W2382179855A5086605052 @default.
• W2382179855 hasConcept C112705442 @default.
• W2382179855 hasConcept C121608353 @default.
• W2382179855 hasConcept C126322002 @default.
• W2382179855 hasConcept C126894567 @default.
• W2382179855 hasConcept C143998085 @default.
• W2382179855 hasConcept C181389837 @default.
• W2382179855 hasConcept C2776694085 @default.
• W2382179855 hasConcept C2780210213 @default.
• W2382179855 hasConcept C2780258809 @default.
• W2382179855 hasConcept C29730261 @default.
• W2382179855 hasConcept C71924100 @default.
• W2382179855 hasConcept C90924648 @default.
• W2382179855 hasConcept C98274493 @default.
• W2382179855 hasConceptScore W2382179855C112705442 @default.
• W2382179855 hasConceptScore W2382179855C121608353 @default.
• W2382179855 hasConceptScore W2382179855C126322002 @default.
• W2382179855 hasConceptScore W2382179855C126894567 @default.
• W2382179855 hasConceptScore W2382179855C143998085 @default.
• W2382179855 hasConceptScore W2382179855C181389837 @default.
• W2382179855 hasConceptScore W2382179855C2776694085 @default.
• W2382179855 hasConceptScore W2382179855C2780210213 @default.
• W2382179855 hasConceptScore W2382179855C2780258809 @default.
• W2382179855 hasConceptScore W2382179855C29730261 @default.
• W2382179855 hasConceptScore W2382179855C71924100 @default.
• W2382179855 hasConceptScore W2382179855C90924648 @default.
• W2382179855 hasConceptScore W2382179855C98274493 @default.
• W2382179855 hasIssue "4" @default.
• W2382179855 hasLocation W23821798551 @default.
• W2382179855 hasLocation W23821798552 @default.
• W2382179855 hasOpenAccess W2382179855 @default.
• W2382179855 hasPrimaryLocation W23821798551 @default.
• W2382179855 hasRelatedWork W114644245 @default.
• W2382179855 hasRelatedWork W1555144605 @default.
• W2382179855 hasRelatedWork W2080955156 @default.
• W2382179855 hasRelatedWork W2376347278 @default.
• W2382179855 hasRelatedWork W2393063064 @default.
• W2382179855 hasRelatedWork W2400119402 @default.
• W2382179855 hasRelatedWork W2606334551 @default.

• next